Table 1.

Efficacy of CAR T-cell therapy in B-cell malignancies.

Disease	Reference	CR/all cases	Follow-up	Long-term efficacy
B-ALL (adult)	NCT01044069	44/53	Median: 29 m	median OS: 12.9 m
B-ALL (pediatric and young adult)	NCT02435849	61/75	12 m	OS rate: 76%
B-CLL	NCT01865617	4/19	24 m	median PFS: 8.5 m
DLBCL	NCT02348216	59/101	Median: 27.1 m	median PFS: 5.9 m
DLBCL	NCT02445248	37/93	Median:14 m	median OS: 12m
DLBCL	NCT02631044	33/73	Median: 8 m	DOR (CR; median): NR
MM (anti-BCMA)	NCT02215967	1/12* (2 VGPR)	6 m	1 VGPR after 6 m
MM (anti-BCMA)	NCT02658929	15/33	Meidan:11.3	median DOR: 10.9

OS, overall survival; PFS, progression-free survival; m, months;

^*stringent complete response (CR); DOR, duration of response; NR, not reached.